Max Healthcare shareholders approve PRSU scheme and Abhay Soi remuneration
- Shareholders approved PRSU Scheme 2026 covering 73.5 lakh shares (~0.76% of capital)
- MoA altered to include medical education, pharma manufacturing, and food services
- Abhay Soi's remuneration as CMD approved with 97.16% votes in favour
- Institutional investors showed higher dissent on CMD remuneration (3.87%) vs other resolutions
*this image is generated using AI for illustrative purposes only.
Max Healthcare Institute Limited members approved a Performance Linked Restricted Stock Unit (PRSU) Scheme 2026, amendments to the company's Memorandum of Association (MoA), and the remuneration of Chairman and Managing Director Abhay Soi via postal ballot on October 19, 2026.
The approval covers the grant of PRSUs to eligible employees of the company and its subsidiary companies. The scheme aligns with SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021. Concurrently, the MoA alteration expands the company's main objects clause to include medical education, pharmaceutical manufacturing, and food services. The voting results were certified by DPV & Associates LLP.
Voting Results Overview
The postal ballot, conducted through remote e-voting from September 20, 2026, to October 19, 2026, saw a high turnout among institutional investors. All four special resolutions passed with significant majorities. Notably, the resolution regarding Abhay Soi's remuneration received slightly lower support from public institutions compared to the other items, though it still passed comfortably.
| Resolution | Description | Votes in Favour (%) | Votes Against (%) |
|---|---|---|---|
| 1 | Approval of PRSU Scheme 2026 for Company employees | 98.20% | 1.80% |
| 2 | Grant of PRSUs to Subsidiary employees | 98.29% | 1.71% |
| 3 | Remuneration for Abhay Soi (CMD) | 97.16% | 2.84% |
| 4 | Alteration of Main Objects Clause (MoA) | 99.99% | 0.01% |
PRSU Scheme 2026 Details
The newly approved PRSU Scheme allows for the issuance of equity shares upon exercise of performance-linked units. The total number of shares covered by these options is capped at 73,50,000 equity shares of face value ₹10 each. This represents approximately 0.76% of the paid-up equity share capital as on August 13, 2026.
Key terms of the scheme include:
| Particulars | Details |
|---|---|
| Regulatory Compliance | In terms of SEBI (SBEB) Regulations, 2021 |
| Total Shares Covered | 73,50,000 equity shares (~0.76% of paid-up capital) |
| Exercise Price | ₹10 per equity share (equal to face value) |
| Exercise Period | Commences on Vesting Date; expires 3 years later |
No options have been granted under the scheme as of the disclosure date. Consequently, details regarding options vested, exercised, or lapsed are currently not applicable.
Expansion of Business Objects
The postal ballot also approved the insertion of three new sub-clauses into Clause III(A) of the MoA, subject to regulatory approvals from the Registrar of Companies or Ministry of Corporate Affairs. These amendments broaden the scope of the company's operations beyond hospital management. This resolution received near-unanimous support, with only 0.01% of votes cast against it.
Medical Education and Training
The first amendment permits the establishment and operation of medical colleges, teaching institutions, and allied health education facilities. This includes undergraduate, postgraduate, and doctoral programs in medicine, nursing, pharmacy, physiotherapy, and healthcare administration.
Pharmaceutical Manufacturing
The second amendment authorizes the manufacturing, formulation, and distribution of pharmaceuticals, including injectables and radiopharmaceuticals. Notably, it explicitly includes the production of Fluorodeoxyglucose (FDG) and other radioisotopes using cyclotron and particle accelerator technologies.
Food and Beverage Services
The third amendment allows the company to operate food and beverage services within its hospitals and educational institutions. This includes cafeterias, canteens, catering facilities, and the supply of related products.
Strategic Implications
The simultaneous approval of employee stock options, business object expansion, and CMD remuneration signals a dual focus on talent retention, vertical integration, and leadership stability. The inclusion of medical colleges and pharmaceutical manufacturing in the MoA suggests a strategic move toward controlling upstream educational and drug production assets, potentially reducing dependency on external vendors for specialized medical supplies and skilled personnel.
What the Numbers Show
The voting data reveals a divergence in shareholder sentiment across the resolutions. While the alteration of business objects (Resolution 4) achieved near-total consensus (99.99% in favour), the approval of Abhay Soi's remuneration (Resolution 3) faced the highest dissent rate at 2.84%. Specifically, public institutions voted 96.13% in favour of Soi's remuneration, compared to over 97.5% in favour for the PRSU schemes. This suggests that while institutional investors broadly support the strategic expansion and employee incentives, there is marginally higher scrutiny regarding executive compensation packages.
Historical Stock Returns for Max Healthcare Institute
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.89% | -6.09% | -19.02% | -16.22% | -29.38% | 0.0% |
What specific regulatory approvals from the MCA or RoC are still pending to operationalize the new pharmaceutical and medical education business lines?
How will the vertical integration into FDG and radiopharmaceutical manufacturing impact Max Healthcare's cost structure and profit margins compared to current third-party sourcing?
What are the anticipated dilution effects on existing shareholders once the 73.5 lakh PRSUs begin vesting and exercising over the next few years?
18
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
